Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v5-EN
Language French English
Date Updated 2022-02-09 2022-02-09
Drug Identification Number 02510162 02510162
Brand name XARELTO XARELTO
Common or Proper name RIVAROXABAN RIVAROXABAN
Company Name BAYER INC BAYER INC
Ingredients RIVAROXABAN RIVAROXABAN
Strength(s) 51.7MG 51.7MG
Dosage form(s) GRANULES FOR SUSPENSION GRANULES FOR SUSPENSION
Route of administration ORAL ORAL
Packaging size 100ML 100ML
ATC code B01AF B01AF
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2022-02-09 2022-02-09
Actual start date 2022-02-08
Estimated end date 2022-03-01 2022-03-01
Actual end date 2022-02-08
Shortage status Avoided shortage Actual shortage
Tier 3 Status No No
Company comments Reason for shortage: Disruptions in Supply chain. Reason for shortage: Disruptions in Supply chain.
Health Canada comments